Izasa will target early adopters who recognize the benefits of utilizing the unique fluid balancing capabilities of RenalGuard in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of contrast-induced nephropathy.
An investigator-sponsored randomized clinical trial to evaluate the use of RenalGuard in the prevention of contrast-induced nephropathy is currently underway in Italy.
Mark Tauscher, president and CEO of PLC Systems, said: “We are extremely pleased with our new agreement with Izasa in Spain. This firm’s strong penetration of the leading cardiovascular centers in Spain will help expose the benefits of RenalGuard to a wider community of physicians.”